目标正常氧血症对成人急性热烧伤无补充氧天数的影响:阶梯楔形整群随机临床试验
这项多中心阶梯楔形整群随机试验将6家美国烧伤中心随机交叉从常规护理转为目标正常氧血症(SpO2 90-96%),纳入1437例成人急性热烧伤患者。目标正常氧血症组与常规护理组的28天无补充氧天数无显著差异(校正均差0.90天,95%CI -0.77至2.57,P=0.29)。目标正常氧血症组至第90天无住院天数更多(校正均差3.47天,95%CI 0.19-6.76),院内死亡率无显著差异(校正HR 0.66,95%CI 0.31-1.42)。目标正常氧血症安全维持了临床结局,但未增加无补充氧天数。
要点
- 在成人急性热烧伤中,目标正常氧血症(SpO2 90-96%)未显著增加28天内无补充氧天数(校正均差0.90天,95%CI -0.77至2.57,P=0.29)。
- 目标正常氧血症组至第90天无住院天数多于常规护理组(校正均差3.47天,95%CI 0.19-6.76)。
- 目标正常氧血症组院内死亡率5.7%(36例) vs 常规护理组8.1%(65例),校正HR 0.66(95%CI 0.31-1.42),无显著差异。
- 目标正常氧血症组低氧血症(SpO2<88%)时间占比0.8% vs 常规护理组0.7%,两组相似。
- 目标正常氧血症组正常氧血症时间占比从常规护理组的77%增至81%,高氧血症(SpO2>96%)时间占比从22%降至17%。
适用人群与场景
- 纳入成人急性热烧伤患者,收治于专科烧伤病房;平均年龄48岁,26%女性,38%全层烧伤,平均烧伤总面积11%。
诊断标准与关键阈值
- 目标正常氧血症定义:外周血氧饱和度(SpO2)90-96%。
- 当SpO2>96%时,指定减少给予的补充氧气。
处置流程与药物剂量
- 目标正常氧血症组:当SpO2>96%时减少给予的补充氧气,目标SpO2 90-96%。
- 常规护理组:补充氧气由治疗临床医生决定。
研究设计与关键结果
- 多中心阶梯楔形整群随机临床试验,6家美国烧伤中心,纳入1437例成人急性热烧伤患者,2021年1月15日至2022年10月15日期间每三个月交叉一次。
- 主要终点28天无补充氧天数:目标正常氧血症组原始均值18.8天 vs 常规护理组17.2天,校正均差0.90天(95%CI -0.77至2.57,P=0.29),无显著差异。
- 至第90天无住院天数:目标正常氧血症组71天 vs 常规护理组70天,校正均差3.47天(95%CI 0.19-6.76)。
- 至第90天院内死亡率:目标正常氧血症组36例(5.7%) vs 常规护理组65例(8.1%),校正HR 0.66(95%CI 0.31-1.42)。
- 低氧血症(SpO2<88%)时间占比:目标正常氧血症组0.8% vs 常规护理组0.7%;正常氧血症时间占比:目标正常氧血症组81% vs 常规护理组77%;高氧血症(SpO2>96%)时间占比:目标正常氧血症组17% vs 常规护理组22%。
证据类型、等级与局限
- 证据类型:多中心阶梯楔形整群随机临床试验;证据等级:治疗/管理,Level I。
对床旁实践的改变
- 在成人急性热烧伤患者中,目标SpO2 90-96%未能增加28天内无补充氧天数,但安全维持了临床结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Supplemental oxygen is essential in caring for adults with acute thermal burns but can expose patients to excess inspired oxygen. We sought to determine the safety and effectiveness of targeting normoxemia (peripheral oxygen saturation [SpO 2 ] 90-96%) in adults with acute thermal burns admitted to a specialized burn unit. We hypothesized that targeting normoxemia would increase the number of supplemental oxygen-free days (SOFDs) and safely reduce exposure to hyperoxemia.
METHODS: In this multicenter cluster-randomized, stepped-wedge trial, we randomized six US burn centers to cross over from usual care to targeted normoxemia at three-month intervals between January 15, 2021, and October 15, 2022. In usual care, supplemental oxygen was determined by treating clinicians. In targeted normoxemia, we specified decreasing administered supplemental oxygen whenever SpO 2 was >96%. The primary outcome was SOFD, defined as the number of days alive and not receiving supplemental oxygen through Day 28. Safety outcomes included hypoxemia (SpO 2 < 88%), in-hospital mortality, and adverse events.
RESULTS: The 1,437 enrolled patients were mean age 48 years, 26% female, 38% with full-thickness burns, and 11% mean total body surface area burned. The proportion of time spent in normoxemia increased from 77% in the usual care group to 81% in the targeted normoxemia group. Time spent with hyperoxemia (SpO 2 > 96%) decreased from 22% to 17%, and hypoxemia was similar between groups (0.7% vs. 0.8%). The raw mean number of SOFD was 18.8 days for targeted normoxemia and 17.2 days for usual care (adjusted mean difference [aMD], 0.90 days; 95% confidence interval [CI], -0.77 to 2.57; p = 0.29). Hospital-free days through Day 90 were greater among the targeted normoxemia group (71 days) than the usual care group (70 days) (aMD, 3.47 days; 95% CI, 0.19-6.76). In-hospital mortality to Day 90 occurred in 36 (5.7%) targeted normoxemia patients and 65 (8.1%) usual care patients (adjusted hazard ratio [aHR], 0.66; 95% CI, 0.31-1.42).
CONCLUSION: Targeting normoxemia did not increase supplemental oxygen-free days among adults with acute thermal burns, but safely maintained clinical outcomes.
LEVEL OF EVIDENCE: Therapeutic Care/Management; Level I.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04534972.
参考来源
- Douin DJ, Rice JD, Xiao M, et al. Effect of targeting normoxemia on supplemental oxygen-free days for adults with acute thermal burns: A stepped wedge cluster randomized clinical trial. J Trauma Acute Care Surg. 2025. PMID: 40604863. doi:10.1097/TA.0000000000004712
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。